1. Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial
- Author
-
Jiang, RC, Wang, D, Zhao, SG, Wang, RZ, Kang, DZ, Zhu, XG, Zhao, ZM, Wei, JJ, Huang, Y, Qu, Y, Sun, XC, Ji, HM, Jiang, XC, Liu, JF, De Zhu, X, Wang, JJ, Tian, Y, Gao, C, Wei, HJ, Zhang, S, Quan, W, Yue, SY, Lei, P, Li, X, Song, LL ; https://orcid.org/0000-0002-6105-1720, Anderson, CS ; https://orcid.org/0000-0002-7248-4863, Zhang, JN, Jiang, RC, Wang, D, Zhao, SG, Wang, RZ, Kang, DZ, Zhu, XG, Zhao, ZM, Wei, JJ, Huang, Y, Qu, Y, Sun, XC, Ji, HM, Jiang, XC, Liu, JF, De Zhu, X, Wang, JJ, Tian, Y, Gao, C, Wei, HJ, Zhang, S, Quan, W, Yue, SY, Lei, P, Li, X, Song, LL ; https://orcid.org/0000-0002-6105-1720, Anderson, CS ; https://orcid.org/0000-0002-7248-4863, and Zhang, JN
- Abstract
Background: Chronic subdural haematoma (CSDH) is a common condition in the elderly that often requires neurosurgical management. For small CSDH, evidence has emerged that statins may reduce haematoma volume and improve outcomes, presumably by reducing local inflammation and promoting vascular repair. We wish to extend this evidence in a study that aims to determine the efficacy and safety of atorvastatin combined with low-dose dexamethasone in patients with CSDH. Methods: The second ATorvastatin On Chronic subdural Hematoma (ATOCH-II) study is a multi-centre, randomized, placebo-controlled, double-blind trial which aims to enrol 240 adult patients with a conservative therapeutic indication for CSDH, randomly allocated to standard treatment with atorvastatin 20 mg combined with low-dose dexamethasone (or matching placebos) daily for 28 days, and with 152 days of follow-up. The primary outcome is a composite good outcome defined by any reduction from baseline in haematoma volume and survival free of surgery at 28 days. Secondary outcomes include functional outcome on the modified Rankin scale (mRS) and modified Barthel Index at 28 days, surgical transition and reduction in haematoma volumes at 14, 28 and 90 days. Discussion: This multi-centre clinical trial aims to provide high-quality evidence on the efficacy and safety of the combined treatment of atorvastatin and low-dose dexamethasone to reduce inflammation and enhance angiogenesis in CSDH. Trial registration: ChiCTR, ChiCTR1900021659. Registered on 3 March 2019, http://www.chictr.org.cn/showproj.aspx?proj=36157.
- Published
- 2021